Stock ZYME ZYMEWORKS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zymeworks Inc.

Equities

ZYME

US98985Y1082

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
8.72 USD +0.11% Intraday chart for Zymeworks Inc. -4.39% -16.07%
May. 02 Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02 Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 68% by 2026.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in debt and has limited leeway for investment
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ZYMEWORKS INC. Stock Zymeworks Inc.
-16.07% 622M -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
B+
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
B+
ARGENX SE Stock argenx SE
-1.69% 21.78B
B
GENMAB A/S Stock Genmab A/S
-10.60% 18.09B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ZYME Stock
  4. Ratings Zymeworks Inc.